Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cu-64 DOTATOC PET-CT imaging in neuroendocrine tumors
2025-524050-34-01Phase 3Withdrawn
- Sponsor
- Voxel
- Start
- Jun 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of copper (64Cu) edotreotide in apudoma (NET), sponsored by Voxel. Primary endpoints: Lesion visualisation bioequivalence and SUVmax bioequivalence. Planned start Jun 2026; status: withdrawn.
02
Drugs
copper (64Cu) edotreotide
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on 2025-524050-34-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524050-34-01.